The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The entire integration and transition of the brands is expected to be completed by March 2022
Key takeaways of Q3FY22 quarter & conference call highlights
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
The KRIVIDA Novus RT-PCR kit can detect the Omicron variant, its sub-lineages, and the Delta variant in 45 minutes
Key takeaways of recent quarter & conference call highlights
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Subscribe To Our Newsletter & Stay Updated
